ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer.

[1]  John A. Benjamin,et al.  Urethral diverticulum in adult female , 1974 .

[2]  W. Whitmore,et al.  Complications of 125iodine implantation and pelvic lymphadenectomy in the treatment of prostatic cancer. , 1979, The Journal of urology.

[3]  J. Oesterling,et al.  Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. , 1988, The Journal of urology.

[4]  T. Stamey,et al.  Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. , 1989, The Journal of urology.

[5]  A. Rademaker,et al.  Re: Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. , 1990, The Journal of urology.

[6]  J. Oesterling,et al.  Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. , 1990, The Journal of urology.

[7]  J. Roy,et al.  CT-based optimized planning for transperineal prostate implant with customized template. , 1991, International journal of radiation oncology, biology, physics.

[8]  J Roy,et al.  An improved method for computerized tomography-planned transperineal 125iodine prostate implants. , 1991, The Journal of urology.

[9]  S. Brosman,et al.  Transrectal ultrasound-guidedinterstitial radiation therapy for localized prostate cancer , 1991 .

[10]  S. Brosman,et al.  Transrectal ultrasound-guided interstitial radiation therapy for localized prostate cancer. , 1991, Progress in clinical and biological research.

[11]  C B Begg,et al.  The effect of local control on metastatic dissemination in carcinoma of the prostate: long-term results in patients treated with 125I implantation. , 1991, International journal of radiation oncology, biology, physics.

[12]  T. Stamey,et al.  Predictive value of contralateral biopsies in unilaterally palpable prostate cancer. , 1992, The Journal of urology.

[13]  D. Beyer,et al.  Guided brachytherapy for treatment of confined prostate cancer. , 1992, Urology.

[14]  Blasko,et al.  Brachytherapy and Organ Preservation in the Management of Carcinoma of the Prostate. , 1993, Seminars in radiation oncology.

[15]  C C Ling,et al.  A CT-based evaluation method for permanent implants: application to prostate. , 1993, International journal of radiation oncology, biology, physics.

[16]  J Roy,et al.  Short-term morbidity from CT-planned transperineal I-125 prostate implants. , 1993, International journal of radiation oncology, biology, physics.

[17]  M. Roach,et al.  Re: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. , 1993, The Journal of urology.

[18]  P. Walsh,et al.  Relationship Between Perineural Tumor Invasion on Needle Biopsy and Radical Prostatectomy Capsular Penetration in Clinical Stage B Adenocarcinoma of the Prostate , 1993, The American journal of surgical pathology.

[19]  H M Pollack,et al.  Use of endorectal surface coil magnetic resonance imaging for local staging of prostate cancer. , 1993, The Journal of urology.

[20]  D. Chan,et al.  The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. , 1993, The Journal of urology.

[21]  P. Walsh,et al.  Influence of capsular penetration on progression following radical prostatectomy: a study of 196 cases with long-term followup. , 1993, The Journal of urology.

[22]  P. Carroll,et al.  Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. , 1994, International journal of radiation oncology, biology, physics.

[23]  P. Walsh,et al.  Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. , 1994, JAMA.

[24]  S Nag,et al.  Transperineal palladium 103 prostate brachytherapy: analysis of morbidity and seed migration. , 1995, Urology.

[25]  J. Blasko,et al.  Prostate specific antigen based disease control following ultrasound guided 125iodine implantation for stage T1/T2 prostatic carcinoma. , 1995, The Journal of urology.

[26]  R. Badalament,et al.  Sextant prostate biopsies. A histopathologic correlation with radical prostatectomy specimens , 1995, Cancer.

[27]  L. Anderson,et al.  Dosimetry of interstitial brachytherapy sources: Recommendations of the AAPM Radiation Therapy Committee Task Group No. 43 , 1995 .

[28]  R. Stock,et al.  Prostate brachytherapy: Improvements in prostate volume measurements and dose distribution using interactive ultrasound guided implantation and three-dimensional dosimetry , 1995 .

[29]  R. Stock,et al.  A modified technique allowing interactive ultrasound-guided three-dimensional transperineal prostate implantation. , 1995, International journal of radiation oncology, biology, physics.

[30]  F. Critz,et al.  Prostate specific antigen‐monitored combination radiotherapy for patients with prostate cancer. I‐125 implant followed by external‐beam radiation , 1995, Cancer.

[31]  K. Wallner,et al.  103Pd brachytherapy and external beam irradiation for clinically localized, high-risk prostatic carcinoma. , 1996, International journal of radiation oncology, biology, physics.

[32]  J. Pow-Sang,et al.  Improvement in dosimetry of ultrasound-guided prostate implants with the use of multiple stabilization needles. , 1996, Medical dosimetry : official journal of the American Association of Medical Dosimetrists.

[33]  J Roy,et al.  Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  P. Unger,et al.  Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma , 1996, Cancer.

[35]  2103 Rectal and urinary morbidity in patients undergoing prostate I-125 implant , 1997 .

[36]  R Oyen,et al.  Cell kinetic measurements in prostate cancer. , 1997, International journal of radiation oncology, biology, physics.

[37]  J. Blasko,et al.  American brachytherapy society survey of current clinical practice for permanent brachytherapy of prostate cancer , 1997 .

[38]  B W Corn,et al.  Effect of edema on the post-implant dosimetry of an I-125 prostate implant: a case study. , 1997, International journal of radiation oncology, biology, physics.

[39]  1008 Transperineal ultrasound guided brachytherapy for early stage prostate cancer update on clinical experience at seven years , 1997 .

[40]  S. Nag.  Principles and practice of brachytherapy , 1997 .

[41]  J J Prete,et al.  Source localization following permanent transperineal prostate interstitial brachytherapy using magnetic resonance imaging. , 1997, International journal of radiation oncology, biology, physics.

[42]  M Dattoli,et al.  A simple method to stabilize the prostate during transperineal prostate brachytherapy. , 1997, International journal of radiation oncology, biology, physics.

[43]  M A Moerland,et al.  Evaluation of permanent I-125 prostate implants using radiography and magnetic resonance imaging. , 1997, International journal of radiation oncology, biology, physics.

[44]  M. Zelefsky,et al.  Long-term results of retropubic permanent 125iodine implantation of the prostate for clinically localized prostatic cancer. , 1997, The Journal of urology.

[45]  A W Partin,et al.  Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. , 1997, JAMA.

[46]  R. Stock,et al.  Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate. , 1998, The Journal of urology.

[47]  J J Prete,et al.  Centralized multiinstitutional postimplant analysis for interstitial prostate brachytherapy. , 1998, International journal of radiation oncology, biology, physics.

[48]  J J Prete,et al.  Timing of computed tomography-based postimplant assessment following permanent transperineal prostate brachytherapy. , 1998, International journal of radiation oncology, biology, physics.

[49]  P. Grimm,et al.  A survey of current clinical practice of permanent prostate brachytherapy in the United States. , 1998, International journal of radiation oncology, biology, physics.

[50]  M. Bolla.  Adjuvant Hormonal Treatment with Radiotherapy for Locally Advanced Prostate Cancer , 1998, European Urology.

[51]  M. Banerjee,et al.  Salvage surgery or salvage radiotherapy for locally recurrent prostate cancer. , 1998, Urology.

[52]  R. Stock,et al.  A dose-response study for I-125 prostate implants. , 1998, International journal of radiation oncology, biology, physics.

[53]  M. Garzotto,et al.  Androgen deprivation with salvage surgery for radiorecurrent prostate cancer: results at 5-year followup. , 1998, The Journal of urology.

[54]  G. Swanson,et al.  Salvage brachytherapy for localized prostate cancer after radiotherapy failure. , 1999, Urology.

[55]  Analysis of the clinical utility of the use of salvage brachytherapy in patients who have a rising PSA after definitive external beam radiation therapy. , 1999, Urology.

[56]  L. Potters,et al.  Urinary morbidity following ultrasound-guided transperineal prostate seed implantation. , 1999, International journal of radiation oncology, biology, physics.

[57]  P. Grimm,et al.  American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. , 1999, International journal of radiation oncology, biology, physics.

[58]  A. K. Levinson,et al.  Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer. , 2000, Journal of Urology.

[59]  American brachytherapy society recommendations for clinical implementation of NIST-1999 standards for (103)palladium brachytherapy. The clinical research committee of the American Brachytherapy Society. , 2000, International journal of radiation oncology, biology, physics.